WINTON GROUP Ltd Invests $562,000 in Bruker Co. (NASDAQ:BRKR)

WINTON GROUP Ltd acquired a new position in shares of Bruker Co. (NASDAQ:BRKR) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 9,584 shares of the medical research company’s stock, valued at approximately $562,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Wealth Enhancement Advisory Services LLC grew its stake in shares of Bruker by 1.4% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 13,287 shares of the medical research company’s stock worth $779,000 after buying an additional 177 shares during the last quarter. Arizona State Retirement System grew its stake in shares of Bruker by 0.7% in the fourth quarter. Arizona State Retirement System now owns 30,725 shares of the medical research company’s stock worth $1,801,000 after acquiring an additional 222 shares during the last quarter. CIBC Asset Management Inc raised its position in shares of Bruker by 5.6% in the 4th quarter. CIBC Asset Management Inc now owns 4,233 shares of the medical research company’s stock worth $248,000 after purchasing an additional 223 shares during the last quarter. UMB Bank n.a. boosted its stake in Bruker by 37.5% in the 4th quarter. UMB Bank n.a. now owns 909 shares of the medical research company’s stock worth $53,000 after purchasing an additional 248 shares in the last quarter. Finally, Blue Trust Inc. grew its position in Bruker by 13.5% during the 4th quarter. Blue Trust Inc. now owns 2,164 shares of the medical research company’s stock valued at $127,000 after purchasing an additional 257 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Trading Down 3.2 %

Shares of BRKR stock opened at $42.08 on Monday. Bruker Co. has a 1 year low of $41.80 and a 1 year high of $94.35. The firm has a fifty day moving average price of $50.54 and a 200-day moving average price of $56.91. The company has a market cap of $6.38 billion, a price-to-earnings ratio of 55.37, a PEG ratio of 2.16 and a beta of 1.18. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.60 and a quick ratio of 0.77.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, topping the consensus estimate of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. As a group, equities analysts predict that Bruker Co. will post 2.69 earnings per share for the current year.

Bruker Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Monday, March 17th were paid a $0.05 dividend. The ex-dividend date was Monday, March 17th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.48%. Bruker’s dividend payout ratio (DPR) is presently 26.32%.

Analysts Set New Price Targets

A number of analysts have commented on the company. Barclays reduced their target price on Bruker from $69.00 to $65.00 and set an “overweight” rating for the company in a report on Monday, February 10th. The Goldman Sachs Group upgraded shares of Bruker from a “sell” rating to a “neutral” rating and set a $60.00 target price on the stock in a research note on Thursday, December 5th. Stifel Nicolaus dropped their price target on shares of Bruker from $70.00 to $57.00 and set a “hold” rating on the stock in a report on Friday, February 14th. Bank of America increased their price objective on shares of Bruker from $78.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, December 13th. Finally, UBS Group assumed coverage on shares of Bruker in a research report on Tuesday, December 10th. They issued a “neutral” rating and a $66.00 target price for the company. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $70.50.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.